Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose Using Positron Emission Tomography (PET) Scanning
| Status: | Completed |
|---|---|
| Conditions: | Alzheimer Disease, Cognitive Studies, Cognitive Studies |
| Therapuetic Areas: | Neurology, Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 50 - 85 |
| Updated: | 8/3/2018 |
| Start Date: | June 9, 2015 |
| End Date: | June 2017 |
Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Varying Risk Factors for Alzheimer's Disease and Subjects on a Ketogenic Diet
This is a single center imaging study that will recruit 30 participants who are enrolled in
the Brain Energy And Memory study (BEAM) protocol. This cohort of patients, aged 50-85, will
receive a maximum of 3 [11C]Acetoacetate (AcAc)/[18F]Fluorodeoxyglucose (FDG) PET scans over
18 weeks as part of this supplemental trial.
the Brain Energy And Memory study (BEAM) protocol. This cohort of patients, aged 50-85, will
receive a maximum of 3 [11C]Acetoacetate (AcAc)/[18F]Fluorodeoxyglucose (FDG) PET scans over
18 weeks as part of this supplemental trial.
This study will examine the brain biodistribution of [11C]AcAc/[18F]FDG, a proxy for
acetoacetate (ketone body)/glucose metabolism, in asymptomatic individuals with increased
risk of Alzheimer's disease, those without identifiable risk of Alzheimer's disease, and
those with early Alzheimer's disease or MCI. Data collected in this study will help provide a
more comprehensive understanding of brain energy metabolism (both glucose and ketone bodies)
in several groups of participants including adults with and without signs of memory
impairment.
acetoacetate (ketone body)/glucose metabolism, in asymptomatic individuals with increased
risk of Alzheimer's disease, those without identifiable risk of Alzheimer's disease, and
those with early Alzheimer's disease or MCI. Data collected in this study will help provide a
more comprehensive understanding of brain energy metabolism (both glucose and ketone bodies)
in several groups of participants including adults with and without signs of memory
impairment.
Inclusion Criteria:
- Mild cognitive impairment or subjective memory complaints
- Stable medical condition and medications
- Ability to complete baseline assessments
Exclusion Criteria:
- History of a clinically significant stroke
- Sensory impairment (visual, auditory)
- Diabetes requiring medication
- Current use of cholesterol/lipid lowering medications, anticonvulsants, drugs with
potential interfering CNS effects (other than cholinesterase inhibitors or memantine),
medications with significant anticholinergic activity, anti-parkinsonian medications
or regular use of narcotic analgesics
- Untreated hypothyroidism or B12 deficiency
We found this trial at
1
site
Click here to add this to my saved trials
